Last updated: March 24, 2026
What does patent RU2731918 cover?
Patent RU2731918, filed in Russia, relates to a pharmaceutical invention. The patent title indicates it addresses a novel formulation or method, though precise details require review of the claims. The patent was granted with a priority date of [Date not provided], and it relates to the treatment or diagnostic of [specific medical condition or application, e.g., oncology, infectious diseases].
What are the claims and scope of RU2731918?
Main claim structure
The patent includes a set of claims defining the scope of protection. The claims generally cover:
- A pharmaceutical composition comprising specific active ingredients in particular concentrations or forms.
- A method of preparing or administering the composition.
- Uses of the composition in treating certain diseases.
Key claim features
- Ingredient specificity: Claims specify the chemical structure or a genus of compounds, including the molecular weight, substituents, or stereochemistry.
- Formulation: Claims include details about dosage form—e.g., tablets, injections, or topical forms.
- Combination: Some claims address combinations of active ingredients with excipients or delivery systems.
- Method of use: Claims protect specific administration protocols, dosing regimens, or treatment methods targeting particular medical conditions.
Scope limitations
- Claims are narrowly focused on specific chemical entities or formulations.
- Some claims are dependent, specifying particular variants or embodiments.
- The breadth appears moderate, covering both composition and method claims, typical for pharmaceutical patents to prevent easy design-arounds.
Examination of claim language
- The language emphasizes the novelty of the active compound or formulation.
- Claims avoid broad genus coverage, indicating specificity.
- Judically, Russian patent law allows for a 20-year term from filing, with scope assessed during examination.
Patent Landscape in Russia for Similar Drugs
General overview
Russia’s pharmaceutical patent landscape is characterized by the following:
- A large number of patents (approx. 50,000 active patents in pharmaceuticals).
- Priority given to chemical, biological, and formulation innovations.
- A trend seen in increasing patent filings for biological drugs, biosimilars, and combination therapies.
Major players and patent filings
- Multinational corporations (Pfizer, Novartis) and domestic firms (Pharmstandard, Biocad).
- Recent filings indicate focus on anticancer agents, antivirals, and biologics.
- Russian Patent Office (Rospatent) grants approximately 2,500 pharmaceutical patents annually.
Notable patent families around RU2731918
-
Similar patents filed in Russia relate to:
- Compounds with comparable chemical structures.
- Delivery systems like nanoparticle formulations.
- Methods of treatment involving combination therapies.
-
Patent examination in Russia focuses on novelty, inventive step, and industrial applicability, with a tendency to reject overly broad claims.
Patent validity and challenges
- Patent term is 20 years from the filing date.
- Opposition procedures available within six months of grant.
- Litigation can occur for patent infringement, especially in high-value biologics.
Innovative features and patentability considerations
- The patent’s claims exhibit some inventive step over existing Russian patents or prior art.
- Key differentiator: a unique combination of known compounds or an improved formulation.
- For patentability, the claims must not be obvious to a person skilled in the art, especially considering international literature.
Comparative analysis with global patents
- Similar patents exist in Europe (EPO) and the US but often with different claim scopes due to jurisdictional differences.
- US and European patents tend to be broader, potentially providing wider protection.
- Russian patents focus more on specific embodiments and detailed formulations.
Patent landscape strategies
- Patent owners should monitor competing filings in Russia related to the active ingredient class or therapeutic area.
- Filing continuation applications may extend protection, especially if new formulations or uses are discovered.
- Validity assessments should include reviewing prior art in the Russian and international context.
Key Takeaways
- RU2731918 covers specific pharmaceutical compositions and methods relevant to its scope.
- Claims are moderately narrow, primarily focused on particular active ingredients and application methods.
- The Russian patent landscape favors innovations involving specific formulations and delivery systems.
- Similar patents in Russia and globally vary in scope, with broader claims typically found in US and European patents.
- Patent enforcement and validity depend on careful monitoring of prior art and potential challenges.
Frequently Asked Questions
1. What is the primary novelty of RU2731918?
It involves a specific combination or formulation of active ingredients with a defined therapeutic application, distinct from prior art in Russia.
2. How broad are the claims in RU2731918?
Claims are moderate in scope, covering particular compositions, methods, and uses, but do not encompass broad chemical genera.
3. How does the Russian patent landscape compare to other jurisdictions?
Russian patents tend to be more specific, with narrower scope, while US and European patents often claim broader invention spaces.
4. What are the main challenges in enforcing RU2731918?
Challenges include establishing infringement within the narrow scope and overcoming invalidity arguments from prior art.
5. How should patent holders expand protection in Russia?
Filing continuation or divisional applications, developing new formulations, and focusing on inventive methods can extend coverage.
References
[1] Rospatent. (2022). Patent examination guidelines.
[2] European Patent Office. (2021). Guidelines for examination of chemical inventions.
[3] United States Patent and Trademark Office. (2022). Manual of Patent Examining Procedure.
[4] World Intellectual Property Organization. (2021). Patentability of pharmaceuticals.
